Notably, Selumetinib is a MEK inhibitor that is clinically available as a pediatric drug for neurofibromatosis type 1, while the rest of the tested MEK inhibitors are routinely used in medical oncology. The gene discussed is MAP2K7; the disease is neurofibromatosis type 1.